INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?
Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.
Cytokinetics Names Jim Daly to Board of Directors
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated ( Nasdaq: CYTK ) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with ...
Cytokinetics Names Jim Daly to Board of Directors - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025.
Knight Therapeutics Reports Second Quarter 2025 Results
Achieved record-high quarterly revenues since inception Increased 2025 financial guidance MONTREAL, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc. GUD ( "Knight" or "the Company" ) , a pan-American ( ex-US ) specialty pharmaceutical company, today reported financial results for its ...
Xencor ( XNCR ) Q2 Revenue Jumps 82%
Xencor ( NASDAQ:XNCR ) , a clinical-stage biopharmaceutical company focused on engineered antibodies for serious diseases, reported second quarter 2025 results on August 6, 2025. The company's GAAP revenue of $43.6 million exceeded analyst estimates by $21.0 million and Revenue ( GAAP ) increased ...
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Actuate Therapeutics, Inc. ( NASDAQ: ACTU ) ( "Actuate" or the "Company" ) , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the ...
Syndax ( SNDX ) Q2 Revenue Jumps 986%
Syndax Pharmaceuticals ( NASDAQ:SNDX ) , a biopharmaceutical company specializing in oncology therapeutics, reported its second-quarter 2025 earnings on August 4, 2025. The most notable news was its substantial GAAP revenue growth, driven primarily by commercial traction for its newly launched ...
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday - Turning Point Brands ( NYSE:TPB ) , Incyte ( NASDAQ:INCY )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Gerald Pascarelli initiated coverage on Turning Point Brands, Inc.
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® ( tafasitamab ) for Follicular Lymphoma in Brazil
MONTREAL, July 31, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc., ( TSX: GUD ) ( "Knight" ) a pan-American ( ex-USA ) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian ...
Why Incyte ( INCY ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand - Incyte ( NASDAQ:INCY )
Incyte Q2 revenue rose 16% to $1.22B, beating estimates; EPS at $1.57 vs. loss of $1.82 YoY Jakafi guidance raised to $3-$3.05 billion for 2025; other oncology products also see upward revisions Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Sanmina, Sarepta Therapeutics, Polaris, Celestica And Other Big Stocks Moving Higher On Tuesday - Rich Sparkle Holdings ( NASDAQ:ANPA ) , Amkor Tech ( NASDAQ:AMKR )
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Shares of Sanmina Corporation SANM rose sharply during Tuesday's session after the company reported better-than-expected quarterly financial results.
Incyte ( INCY ) Surpasses Q2 Earnings and Revenue Estimates
Incyte (INCY) delivered earnings and revenue surprises of +12.95% and +5.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Labcorp Posts 9.5 Percent Gain in Q2
Laboratory Corporation of America ( NYSE:LH ) , a global leader in diagnostics and drug development, reported results for Q2 2025 on July 24, 2025. The earnings release highlighted strong GAAP revenue growth that beat consensus estimates, adjusted earnings per share ( non-GAAP ) that outpaced ...
Why Is Testing Giant Labcorp Stock Surging On Thursday? - Labcorp Hldgs ( NYSE:LH )
Q2 adjusted EPS rose to $4.35 from $3.94, beating the $4.17 estimate. FY25 earnings guidance raised to $16.05-$16.50 vs prior range of $15.70-$16.40. A new wave of value and momentum stocks could be setting up for major moves-and Tim Melvin will name them live this Wednesday. Secure access here.
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
Labcorp ( LH ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Need a quote from one of our analysts? Email [email protected] ( NYSE:LH ) reported double-digit top-line growth and margin expansion for fiscal Q2 2025, raising full-year 2025 guidance and attributing performance to continued strength in diagnostics and momentum in ...
Alnylam Pharmaceuticals ( ALNY ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.
Incyte ( INCY ) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is BrightSpring Health Services, Inc. ( BTSG ) Outperforming Other Medical Stocks This Year?
Here is how BrightSpring Health Services, Inc. (BTSG) and Incyte (INCY) have performed compared to their sector so far this year.
INCY or TECH: Which Is the Better Value Stock Right Now?
INCY vs. TECH: Which Stock Is the Better Value Option?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Notable Insider Move: William Meury Takes Part In Options Exercise At Incyte, Resulting In $0 - Incyte ( NASDAQ:INCY )
Highlighted on June 30, it was unveiled in an SEC filing that Meury, Chief Executive Officer at Incyte INCY, executed a significant transaction involving the exercise of company stock options. What Happened: A notable Form 4 filing on Monday with the U.S.
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.
FDA Extends INCY's Application for Opzelura Label Expansion
FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
QGEN teams with GENCURIX to expand its digital PCR IVD offerings, aiming to strengthen its precision diagnostics arm.
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.
QGEN Stock Rises in After Market Following Partnership With Incyte
QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.
Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses - Incyte ( NASDAQ:INCY )
86% of patients on 400+ mg of INCA033989 had a complete or partial hematologic response. 89% of patients showed a reduction in mutCALR VAF, with 21% achieving >50% drop in just three cycles. Historic Summer Setup: 3 "Power Patterns" Triggering in the next 75 Days - Get The Details Now
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket - Battalion Oil ( AMEX:BATL ) , AIRO Group Holdings ( NASDAQ:AIRO )
Shares of Incyte Corporation INCY rose sharply in today's pre-market trading. QIAGEN and Incyte disclosed a precision medicine collaboration to develop companion diagnostics for patients with mutant CALR-expressing Myeloproliferative Neoplasms ( MPNs ) .
Qiagen ( QGEN ) Up 8.1% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Halozyme Therapeutics ( HALO ) Down 23.2% Since Last Earnings Report?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 ( GLOBE NEWSWIRE ) -- HUTCHMED ( China ) Limited ( "HUTCHMED" ) ( Nasdaq/AIM:HCM. HKEX:13 ) and Innovent Biologics, Inc. ( "Innovent" ) ( HKEX: 01801 ) today jointly announce that the New Drug Application ( "NDA" ) for the combination ...
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma - HUTCHMED ( China ) ( NASDAQ:HCM )
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 ( GLOBE NEWSWIRE ) -- HUTCHMED ( China ) Limited ( "HUTCHMED" ) ( Nasdaq/AIM:HCM.
LH Stock Rises Following the Expansion of Precision Oncology Portfolio
Labcorp expands its precision oncology lineup with new cancer tests and a global diagnostic tool.
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies
Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies are part of the Zacks Industry Outlook article.
4 Medical Product Stocks to Watch From a Challenging Industry
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® ( revumenib ) and Niktimvo™ ( axatilimab-csfr )
- Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and ...
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® ( revumenib ) and Niktimvo™ ( axatilimab-csfr ) - Syndax Pharmaceuticals ( NASDAQ:SNDX )
- Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r - - Axatilimab abstracts highlight the robust responses observed in different organs and subgroups of patients with ...
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update - Merus ( NASDAQ:MRUS )
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028
Annual NMDP ( SM ) Gala in New York City Raises Over a Half Million Dollars, Enabling More Patients to Receive Life-Saving Cell Therapy
MINNEAPOLIS, May 06, 2025 ( GLOBE NEWSWIRE ) -- NMDPSM hosted its annual gala in New York on Thursday, May 1, raising $525,000-- funds which will support patient financial assistance and innovative cell therapy research to improve post-transplant outcomes and expand treatment access so every ...
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Incyte ( INCY ) Q1 Earnings and Revenues Top Estimates
Incyte (INCY) delivered earnings and revenue surprises of 14.85% and 4.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
